Synopsis Studies report that deaths from pertussis in the post vaccine era are largely restricted to unvaccinated infants younger than 8 weeks of age. Moreover, a single infant dose of pertussis vaccine provides significant protection against mortality. This week’s “ MED FACT ” discusses a phase 3 randomized, nonblinded clinical trial from JAMA Pediatrics, “ Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial ”, 2018. Authors: N. Wood, T.
Nolan, H. Marshall, et.al. Key Takeaways The monovalent acellular Pertussis (aP) vaccine is immunogenic and safe in neonates. Objective: To compare the responses of IgG antibody with vaccine antigens at 6, 10, 24, and 32 weeks in newborns receiving a combination of aP vaccine and hepatitis B vaccine (HBV) or HBV alone. Study Type: Phase 3 randomized, nonblinded clinical trial Participants: 440 What…
